Trial Profile
A Multicenter, Open-label, Single-arm, Extension Study to Assess Long-term Safety of Evolocumab Therapy in Patients With Clinically Evident Cardiovascular Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Dec 2023
Price :
$35
*
At a glance
- Drugs Evolocumab (Primary)
- Indications Cardiovascular disorders; Dyslipidaemias; Hypercholesterolaemia
- Focus Adverse reactions
- Acronyms FOURIER OLE
- Sponsors Amgen
- 13 Nov 2023 Results from FOURIER and FOURIER OLE assessing Long-Term Efficacy of Evolocumab in Patients With and Without Multivessel Coronary Artery Disease, presented at the American Heart Association Scientific Sessions 2023
- 01 Mar 2023 Results published in the Amgen media release.
- 01 Mar 2023 According to Amgen media release, new data from this study will be presented at the American College of Cardiology's 72nd annual scientific session together with World Heart Federation's World Congress of Cardiology (ACC.23/WCC) in New Orleans, LA from 4th to 6th March 2023.